Nasopharyngeal Carcinoma Clinical Trial
Official title:
Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy: a Randomised-controlled Trial
In Hong Kong, every 30 and 12.9 in 100,000 males and females respectively has nasopharyngeal
carcinoma (NPC). With early detection and advances in medical care, the number of NPC
survivors post radiotherapy is rapidly growing in Hong Kong. One of the most distressing
consequences post radiotherapy for NPC patients is swallowing disorder, or dysphagia.
Dysphagia in NPC patients almost certainly cause frequent chest infection, dehydration,
malnutrition and limitations to concurrent treatment such as oral medication. Given the
existing large costs NPC patients incur to the healthcare system, dysphagia only serves to
further inflate the soaring costs.
In an attempt to reduce dysphagia related costs to the healthcare system, swallowing
rehabilitation is offered to NPC patients. Currently, two major swallowing rehabilitation
approaches are commonly adopted. The first is traditional rehabilitation, which involves
patients performing various oropharyngeal exercises aimed at improving swallowing
physiology. The other swallowing rehabilitation approach is transcutaneous electrical
stimulation, which entails using small amount of electric current to increase muscle
strength while patients are engaged in swallowing activities. These two methods are proven
as effective in patients with stroke and head and neck carcinoma patients. Neither of these
methods, nevertheless, yields any efficacy studies in treating NPC patients. Yet, clinicians
continue to use either one or both rehabilitation methods as swallowing rehabilitation.
This study aims to address the gap in efficacy studies on swallowing rehabilitation for NPC
patients post radiotherapy. The research results should provide justification for
rehabilitation time, clinicians' efforts, costs involved and resources used in
rehabilitating the swallowing difficulties of the NPC patients.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | December 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - able 18 years of age - undergone primary radiotherapy or chemoradiotherapy as the treatment - are expected to complete the 12 month follow-up Exclusion Criteria: - prior history of head and neck surgery except biopsies of the NP or the neck nodes - previous history or having a concurrent neoplasm other than NPC - other severe medical problems that might contribute to dysphagia, e.g. cerebral vascular accident, neuromuscular diseases, respiratory diseases that may cause dysphagia - present contraindications for the use of electrical stimulation which include pregnancy, pacemaker, other implanted electrodes or significant reflux - non-oral feeding is contemplated in prior to treatment - inability to complete the assessment including cognitive impairment - of a low life expectancy related to NPC or other illnesses - history of dysphagia prior to radiotherapy or chemoradiotherapy |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Hong Kong | Queen Elizabeth Hospital | Kowloon | |
Hong Kong | Prince of Wales Hospital | Shatin | New Territories |
Lead Sponsor | Collaborator |
---|---|
Chinese University of Hong Kong | Prince of Wales Hospital, Shatin, Hong Kong, Queen Elizabeth Hospital, Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Penetration-Aspiration Scale | Each subject will undergo Fiberoptic Endoscopic Evaluation of Swallowing (FEES) to identify penetration and aspiration risks of each consistency. Subjects will be assessed on five different consistencies: thin fluids, honey-thick fluids, pureed diet, soft diet and biscuits. Therefore, five penetration-aspiration scores will be generated for each assessment. Scores will be obtained at baseline, post rehabilitation, six months after baseline and one year after baseline for comparison. |
Up to 1 year after rehabilitation program | Yes |
Secondary | Functional Assessment of Cancer Therapy - Nasopharyngeal (FACT-NP) | The validated FACT-NP is a Chinese QOL questionnaire that evaluates the rehabilitation outcomes specifically for NPC patients. Among the sixteen NPC sub-scale items, seven are specific to dysphagia. The total score and dysphagia specific scores will be analysed. Scores will be obtained at baseline, post rehabilitation, six months after baseline and one year after baseline for comparison. |
Up to 1 year after rehabilitation program | No |
Secondary | Self-rated Swallowing Score | A questionnaire based on patient's perception of existing feeding difficulties. Scores will be obtained at baseline, post rehabilitation, six months after baseline and one year after baseline for comparison. | up to 1 year after rehabilitation program | No |
Secondary | Voice Handicap Index - 30 | This self-assessment scale consists of 30 items that measures the voice-related quality-of-life over three domains: functional, physical, and emotional. Scores will be obtained at baseline, post rehabilitation, six months after baseline and one year after baseline for comparison. | Up to 1 year after rehabilitation program | No |
Secondary | Oral Assessment Guide | This 24 point tool comprise of eight categories: swallow, voice, lips, saliva, tongue, gingival, teeth and mucous membrane. Each category is rated by a scale of 1 (normal), 2 (some abnormality) and 3 (severely abnormal). Scores can be obtained at baseline, post rehabilitation, six months after baseline and one year after baseline for comparison. | Up to 1 year after rehabilitation program | No |
Secondary | Perceptual Evaluation of Voice | Four vocal parameters, overall severity, roughness, breathiness and strain, will be rated on a 10-point equal-appearing interval scale by the attending speech therapists. Scores will be obtained at all 4 assessment time point for comparison. | Up to 1 year after rehabilitation program | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979961 -
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT06055816 -
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05547971 -
Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
|
||
Not yet recruiting |
NCT05020925 -
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04548271 -
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04547088 -
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT02795169 -
Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02801487 -
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02569788 -
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT02237924 -
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT02044562 -
Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
|
N/A | |
Terminated |
NCT01694576 -
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
|
Phase 2 | |
Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Completed |
NCT01271439 -
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT00535795 -
Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA
|
Phase 3 | |
Completed |
NCT00379262 -
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT03398980 -
Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy
|
N/A | |
Completed |
NCT01309633 -
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
|
Phase 2 |